---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-096257"
form_type: "8-K"
ticker: "SRPT"
cik: "0000873303"
company_name: "Sarepta Therapeutics, Inc."
filed_at: "2025-07-16T23:59:59+00:00"
generated_at: "2026-05-18T06:23:49.923127+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Sarepta cuts 36% workforce, reports $513M Q2 revenue, agrees to ELEVIDYS black box warning

## Summary
- Workforce reduction of ~36% (~500 employees); one-time charge of $32-37M in Q3 2025; annual cost savings of ~$400M.
- Preliminary Q2 2025 net product revenue $513M: ELEVIDYS $282M, PMOs $231M; cash & investments ~$850M.
- FDA requested black box warning for acute liver injury/failure in ELEVIDYS label; Sarepta agrees, resolving material issues for ambulant patients.
- Pipeline reprioritized to focus on siRNA platform; most LGMD gene therapies paused, except SRP-9003 BLA expected H2 2025.
- Executive changes: Ian Estepan as President/COO, Louise Rodino-Klapac as President R&D, Ryan Wong as CFO; Dallan Murray departs.

## SEC filing metadata
- accession: 0000950170-25-096257
- form_type: 8-K
- ticker: SRPT
- cik: 0000873303
- company_name: Sarepta Therapeutics, Inc.
- filed_at: 2025-07-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 2.05, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/873303/000095017025096257/0000950170-25-096257-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/873303/000095017025096257/srpt-20250714.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-096257
- JSON: https://secwatch.observer/filing/0000950170-25-096257.json
- Plain text: https://secwatch.observer/filing/0000950170-25-096257.txt

## Key facts
- Restructurings & Charges
  Sarepta Therapeutics, Inc. announced a restructuring with charges of between approximately $32 million and $37 million (approximately 36% of the Company's workforce).
  - Type: restructuring
  - Charge: between approximately $32 million and $37 million
  - Headcount: approximately 36% of the Company's workforce
  source text: on July 14, 2025, the Board of Directors of the Company (the “Board”) approved a reduction in force, representing approximately 36% of the Company’s workforce. As a result of this reduction in force, the Company estimates that it will record a one-time charge in the third quarter of 2025 related to employee termination benefits, including severance, between approximately $32 million and $37 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/873303/000095017025096257/0000950170-25-096257-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.